NCT05652855 - Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

July 31, 2026

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG

MHB088C for Injection

MHB088C for Injection, an antibody drug-conjugated molecule (ADC)

Trial Locations (3)

Cabrini Health, Melbourne

Pindara Private Hospital, Gold Coast

Southern Oncology Clinical Research Unit, Adelaide